Nobel laureate Doudna's biotech Mammoth hits over $1 bln in valuation
Summary
Nobel Prize in chemistry winner, American scientist Jennifer Doudna poses with her medal outside her house in Berkeley, California, U.S., in this undated handout image obtained by Reuters on December 9, 2020. Sept 9 (Reuters) - Mammoth Biosciences, co-founded by Nobel laureate Jennifer Doudna, touched a valuation of more than $1 billion after raising $150 million in its latest funding round. "Weve always known that many of these proteins could be transformative for therapeutic applications as well," said Chief Executive Officer Trevor Martin, who co-founded the company with Doudna and other members of her lab. Martin said the discovery by Mammoth of newer and smaller proteins such as CAS14 could help overcome hurdles faced by older ones, including the CAS9 editing tool. The company, which counts Apple Incs (AAPL.O) Chief Executive Tim Cook and Alphabets (GOOGL.O) Verily as investors, declined to comment on a specific timeline for when a drug could begin being tested in humans.
Classifications
AskAI Classifications
LabelsLinked Companies
